Key Highlights

  • Revenue for the third quarter increased 68% to USD 33.5 million from USD 19.9 million, driven by consumables, which grew 79% to USD 17.8 million, and instruments, up 50% to USD 8.5 million.
  • Full-year 2026 Revenue guidance now runs USD 121 million to USD 123 million, up from USD 116 million to USD 120 million, implying 64% growth at the midpoint for Alamar Biosciences (NASDAQ:ALMR).
  • A Margin rise to 61.5% from 59.7% was outweighed by an 81% jump in operating expenses to USD 35.8 million, which pushed the net loss to USD 13.3 million from USD 8.0 million.
  • Cash, short-term investments and restricted cash stood at USD 231.5 million on September 30, 2026, and President Tod White plans to retire at year-end.

Consumables and Instruments Carry a 68% Revenue Gain

Alamar Biosciences (NASDAQ:ALMR) released third-quarter 2026 figures on November 3, 2026, with a conference call that afternoon at 4:30 p.m. ET. Sales reached USD 33.5 million, compared with USD 19.9 million a year earlier. Demand for multiplex panels lifted consumables 79%, new system placements raised instruments 50%, and custom assay development pushed services up 69%. For the first time, biopharma customers represented the largest revenue slice. The firm sells precision proteomics platforms built on its NULISA technology and ARGO HT System, which pick up low-concentration protein biomarkers in blood. Nine-month revenue totaled USD 89.0 million against USD 49.2 million, about 81% higher by simple arithmetic.

Margins Improve, but Spending Grows Even Faster

Gross margin climbed to 61.5% thanks to cheaper instruments, higher average consumable prices, better service profitability and a richer product mix. Operating expenses, however, surged 81% to USD 35.8 million as the company spent on headcount, infrastructure and R&D supplies and absorbed added public-company costs. Stock Compensation inside operating costs was USD 3.9 million compared with USD 0.7 million the year before. The operating loss widened to USD 15.1 million from USD 7.9 million, and the net loss reached USD 13.3 million, or USD 0.19 a share. Per-share comparisons are skewed because weighted shares jumped to 69.1 million from 11.6 million after the initial public offering, and no convertible preferred stock remains on the balance sheet. Interest income of USD 2.2 million softened the loss.

Implied Fourth Quarter, Leadership Transition and Liquidity

Taking nine-month revenue out of the new full-year range implies fourth-quarter revenue of roughly USD 32.0 million to USD 34.0 million (own arithmetic), close to the third quarter's USD 33.5 million, which leaves little scope for further sequential expansion. Cash and investments of USD 231.5 million sit against zero term debt, compared with USD 9.8 million at the close of 2025. Key risks include fierce proteomics rivalry, dependence on academic researchers backed by government funds, possible FDA oversight and Manufacturing complexity. Because the company was recently listed as a small cap, shares can trade sparsely, bid-ask spreads may widen and quoted moves can reverse. President Tod White retires December 31, 2026 and will advise through June 2027.

Where Things Stand

Yes, the company raised its 2026 revenue range to USD 121 million to USD 123 million after a 68% quarterly gain, because third-quarter sales ran well ahead of last year and the UK Biobank and GSK programs enlarge the sample Volume behind its consumables. Alamar Biosciences (NASDAQ:ALMR) still posts losses, since operating costs outpace revenue, and the new range implies a fourth quarter close to the third. The USD 231.5 million cash pile provides room to keep funding growth, while the president's year-end retirement is a leadership change to track. Biopharma mix shifts and academic funding conditions are the main swing factors.